December 15: The Week in Cancer News
Study finds breast cancer survivors can opt for less frequent screening, and people with physical disabilities often encounter discrimination in cancer care.
Progress Against Cancer
Study finds breast cancer survivors can opt for less frequent screening, and people with physical disabilities often encounter discrimination in cancer care.
In 1994, at the age of 40, Ginny Mason, RN, began noticing some concerning differences in the size and color of one of her breasts, accompanied by new shooting pains. The radiologist who reviewed...
Belzutifan is now available for certain patients with kidney cancer whether or not they have von Hippel-Lindau disease. The U.S. Food and Drug Administration (FDA) has approved belzutifan (Welireg) for the treatment of patients...
The FDA has approved eflornithine to prevent relapse after standard-of-care therapy for neuroblastoma. The U.S. Food and Drug Administration (FDA) has approved eflornithine (Iwilfin) to reduce the risk of relapse in adult and pediatric...
Researchers focus on assessing quality of life and toxicity risks in people with breast cancer.
Less radiation explored in multiple studies at San Antonio Breast Cancer Symposium, and National Cancer Institute writes next precision medicine chapter.
Study finds supervised physical activity can help improve quality of life and reduce fatigue among people with metastatic breast cancer.
A breast cancer diagnosis can pose innumerable challenges, and with the average age at diagnosis dropping, the impact of treatment on fertility can present yet another heartache. For a woman who wants to conceive,...
PSMA PET imaging is helping clinicians more accurately stage prostate cancer and provide precision treatment.
Each December, an impressive cohort of breast cancer researchers gathers for the San Antonio Breast Cancer Symposium (SABCS), one of the largest breast cancer meetings in the world. Nestled between the holiday lights bedecking...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More